Valneva ends chikungunya vaccine deal with India's Serum Institute
Source: SeekingAlpha
2025-12-31 12:36:35 ET
More on Valneva
- Valneva SE (VALN) Q3 2025 Earnings Call Transcript
- Valneva SE 2025 Q3 - Results - Earnings Call Presentation
- First locally-acquired chikungunya case reported in U.S. since 2019
- Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing
- Seeking Alpha’s Quant Rating on Valneva
Read the full article on Seeking Alpha
For further details see:
Valneva ends chikungunya vaccine deal with India’s Serum Institute
Valneva SE
NASDAQ: VALN
VALN Trading
-3.96% G/L:
$11.04 Last:
1,279 Volume:
$11.14 Open:
VALN Latest News
October 01, 2025 04:20:00 pm
Ongoing Valneva SE (VALN) Investigation: Protect Your Rights - Contact Levi & Korsinsky
VALN Stock Data
$798,793,290
73,508,485
N/A
10
N/A
Biotechnology & Life Sciences
Healthcare
FR
Lyon
